Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Portfolio Pulse from Vandana Singh
CytomX Therapeutics Inc (NASDAQ:CTMX) released initial data from its CX-904 Phase 1a study, showing a favorable safety profile and confirmed anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. The study, which enrolled 35 patients, demonstrated measurable tumor reduction in eight patients, including two with pancreatic cancer showing confirmed partial responses. Despite the positive clinical data, CTMX shares dropped 46.1% to $2.259. Analysts from Wedbush upgraded CTMX to Outperform, raising the price target from $3 to $8, citing promising technology validation and clinical pipeline progression. However, H.C. Wainwright remains cautious, awaiting a broader dataset for pancreatic cancer due to historical clinical challenges in this subtype, maintaining a Neutral rating without a price target.
May 09, 2024 | 6:59 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CytomX Therapeutics Inc released positive initial data from its CX-904 Phase 1a study but saw a significant stock price drop. Analysts are divided, with Wedbush upgrading the stock and raising the price target, while H.C. Wainwright remains neutral awaiting more data.
The positive clinical data from the CX-904 study typically would suggest a positive impact on CTMX's stock price. However, the significant drop in share price indicates market concerns or unmet expectations, possibly due to the cautious stance from analysts like H.C. Wainwright. Wedbush's upgrade and price target increase reflect optimism about the company's technology and pipeline, but the overall market reaction was negative, likely due to the complex nature of pancreatic cancer treatment and historical challenges in this area.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100